Evaluation of drug activity in women with breast cancer and no previous Herceptin treatment - CHIVE
Study identifier:D0102C00019
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients with Early Breast Cancer who are Ineligible for Treatment with trastuzumab as defined by IHC status
Medical condition
Breast Neoplasm
Phase
Phase 1
Healthy volunteers
No
Study drug
Drug-AZD8931, Drug-Placebo
Sex
Female
Actual Enrollment
3
Study type
Interventional
Age
18 Years - 150 Years
Date
Study Start Date: 01 Aug 2012
Primary Completion Date: 01 Dec 2012
Study Completion Date: 01 Dec 2012
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Jan 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: AZD8931 AZD8931 | Drug: Drug-AZD8931 Active drug for biological activity |
| Placebo Comparator: Placebo Placebo | Drug: Drug-Placebo Placebo comparator for biological activity comparison |
Contacts
Investigators
Principal Investigator
Serban Ghiorghiu
Internal
